Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Crinetics Pharmaceuticals (CRNX) has announced its participation in two major healthcare investor conferences in March 2025. The company will be present at the TD Cowen 45th Annual Healthcare Conference in Boston, where management will participate in a fireside chat on March 3 at 11:10 a.m. ET. Additionally, they will attend the Leerink Global Healthcare Conference in Miami, featuring another fireside chat on March 10 at 4:20 p.m. ET.
Both events will be available via webcast, with live and archived versions accessible through the Events & Presentations page in the Investors section of Crinetics' website. Investors interested in one-on-one meetings with management are encouraged to contact their conference representatives.
Crinetics Pharmaceuticals (CRNX) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a marzo 2025. L'azienda sarà presente al TD Cowen 45th Annual Healthcare Conference a Boston, dove la direzione parteciperà a una chat informale il 3 marzo alle 11:10 ET. Inoltre, parteciperanno al Leerink Global Healthcare Conference a Miami, che includerà un'altra chat informale il 10 marzo alle 16:20 ET.
Entrambi gli eventi saranno disponibili tramite webcast, con versioni live e archiviate accessibili attraverso la pagina Eventi e Presentazioni nella sezione Investitori del sito web di Crinetics. Gli investitori interessati a incontri individuali con la direzione sono invitati a contattare i rappresentanti della conferenza.
Crinetics Pharmaceuticals (CRNX) ha anunciado su participación en dos importantes conferencias para inversores en el sector de la salud en marzo de 2025. La empresa estará presente en la TD Cowen 45th Annual Healthcare Conference en Boston, donde la dirección participará en una charla informal el 3 de marzo a las 11:10 a.m. ET. Además, asistirán a la Leerink Global Healthcare Conference en Miami, que contará con otra charla informal el 10 de marzo a las 4:20 p.m. ET.
Ambos eventos estarán disponibles a través de webcast, con versiones en vivo y archivadas accesibles a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de Crinetics. Se anima a los inversores interesados en reuniones uno a uno con la dirección a contactar a sus representantes de la conferencia.
Crinetics Pharmaceuticals (CRNX)는 2025년 3월에 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 회의에 참석하며, 경영진은 3월 3일 오전 11시 10분 ET에 파이어사이드 챗에 참여할 예정입니다. 또한, 그들은 마이애미에서 열리는 Leerink Global Healthcare Conference에도 참석하며, 3월 10일 오후 4시 20분 ET에 또 다른 파이어사이드 챗이 있을 것입니다.
두 행사 모두 웹캐스트를 통해 제공되며, Crinetics 웹사이트의 투자자 섹션에 있는 이벤트 및 프레젠테이션 페이지를 통해 실시간 및 아카이브 버전을 이용할 수 있습니다. 경영진과 1:1 미팅을 원하는 투자자들은 컨퍼런스 담당자에게 연락할 것을 권장합니다.
Crinetics Pharmaceuticals (CRNX) a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en mars 2025. L'entreprise sera présente à la TD Cowen 45th Annual Healthcare Conference à Boston, où la direction participera à une discussion informelle le 3 mars à 11h10 ET. De plus, ils assisteront à la Leerink Global Healthcare Conference à Miami, qui comportera une autre discussion informelle le 10 mars à 16h20 ET.
Les deux événements seront accessibles par webcast, avec des versions en direct et archivées disponibles sur la page Événements et Présentations dans la section Investisseurs du site web de Crinetics. Les investisseurs intéressés par des réunions individuelles avec la direction sont encouragés à contacter leurs représentants de conférence.
Crinetics Pharmaceuticals (CRNX) hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Gesundheitswesen im März 2025 angekündigt. Das Unternehmen wird auf der TD Cowen 45th Annual Healthcare Conference in Boston präsent sein, wo das Management am 3. März um 11:10 Uhr ET an einem Fireside-Chat teilnehmen wird. Darüber hinaus werden sie an der Leerink Global Healthcare Conference in Miami teilnehmen, die einen weiteren Fireside-Chat am 10. März um 16:20 Uhr ET umfasst.
Beide Veranstaltungen werden über Webcast verfügbar sein, mit Live- und archivierten Versionen, die über die Seite Veranstaltungen & Präsentationen im Investorenbereich der Website von Crinetics zugänglich sind. Investoren, die an Einzelgesprächen mit dem Management interessiert sind, werden ermutigt, ihre Konferenzvertreter zu kontaktieren.
- None.
- None.
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL.
TD Cowen 45th Annual Healthcare Conference
Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time
Webcast link HERE
Leerink Global Healthcare Conference
Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time
Webcast link HERE
The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
When is Crinetics Pharmaceuticals (CRNX) presenting at the TD Cowen Healthcare Conference in March 2025?
What time is CRNX's presentation at the Leerink Global Healthcare Conference?
How can investors access CRNX's March 2025 conference presentations?
How can investors arrange one-on-one meetings with CRNX management at these conferences?
